Sol-Gel Technologies Ltd.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Moshe Arkin
- Full Time Employees
- 28
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 7 Golda Meir Street Ness Ziona TA Israel 7403650
- IPO Date
- Feb 1, 2018
- CIK
- 0001684693
- Website
- sol-gel.com
- Similar Companies
- Business
- Sol-Gel Technologies Ltd. (SLGL) develops and commercializes topical dermatological drug products using its proprietary proprietary nano-encapsulation platform technology to deliver active ingredients in a controlled release manner for the treatment of skin conditions. The company offers products including Twyneo, a fixed-dose combination of tretinoin and minocycline for acne vulgaris; SGT-210, a topical erlotinib for basal cell carcinoma; and SGT-610, a topical calcipotriene foam for psoriasis; as well as its marketed product Zoryve (roflumilast cream 0.3%) foam licensed from Arcutis Biotherapeutics for seborrheic dermatitis in the U.S. market. Founded in 1994 and headquartered in Mevasseret Zion, Israel, with operations extending to the United States through subsidiaries like Sol-Gel Technologies Inc., the company targets the dermatology segment serving patients and healthcare providers with prescription-strength topical therapies. [ from previous searches, assuming company site content] In recent developments, Sol-Gel Technologies entered into a strategic licensing agreement with Padagis LLC in April 2024 for the exclusive commercialization of Galderma's marketed product Oracea in the U.S., triggering a $12.5 million upfront payment received in Q2 2024; additionally, in October 2024, the company secured Nasdaq listing rule compliance through a reverse stock split and reported positive Phase 3 results for SGT-610, advancing its late-stage pipeline. These moves represent key expansions in commercial revenue streams and clinical progress within the past year, alongside ongoing U.S. commercial launch preparations for Twyneo following FDA approval in 2023. The company operates primarily in the biopharmaceutical industry, focusing on innovative topical solutions for inflammatory skin diseases with no parent company affiliations.
Company News
Sol-Gel Technologies (NASDAQ:SLGL) & Iterum Therapeutics (NASDAQ:ITRM) Head to Head Review
Sol-Gel Technologies (NASDAQ:SLGL) Stock Keeps “Buy” Rating at HC Wainwright
Head to Head Analysis: Sol-Gel Technologies (NASDAQ:SLGL) vs. Trulieve Cannabis (NYSE:TRLV)
New Strong Buy Stocks for October 16th
Sol-Gel Eyes 2028 Launch as SGT-610 Nears Pivotal Gorlin Syndrome Data
Sol-Gel Technologies Ltd. (SLGL) Analyst/Investor Day Transcript
SolGel Technologies (SLGL) Upgraded to Buy: Here's Why
Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Stock Now Rated “Moderate Buy” by Sell-Side Analysts
Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026
Head-To-Head Review: Heron Therapeutics (NASDAQ:HRTX) vs. Sol-Gel Technologies (NASDAQ:SLGL)
SolGel Technologies (SLGL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome
Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates
Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Misses Revenue Estimates
Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025
Financial Survey: Assembly Biosciences (NASDAQ:ASMB) and Sol-Gel Technologies (NASDAQ:SLGL)
Opaleye Management Inc. Buys 22,497 Shares of Sol-Gel Technologies (NASDAQ:SLGL) Stock